Physician profile
Randy E Benish
NPI 1215905617
$3,535.25
in general payments reported to CMS, 2019-2025
26 companies · $2,762 in 2025
The $2,762 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.01 · 2022: $63.06 · 2023: $19.01 · 2024: $624 · 2025: $2,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,328 · Education: $77.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,328.14 |
| Education | $77.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $645.85 | 2024-2025 | |
| Ucb, INC. | $489.17 | 2024-2025 | Bimzelx |
| Amgen INC. | $415.68 | 2024-2025 | Tavneos, Otezla, Krystexxa |
| Ani Pharmaceuticals, INC. | $315.99 | 2024-2025 | Purified Cortrophin Gel |
| Janssen Biotech, INC. | $261.74 | 2024-2025 | Tremfya, Simponi Aria, Remicade |
| Glaxosmithkline, LLC. | $255.59 | 2024-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $162.60 | 2024-2025 | |
| Organon LLC | $135.97 | 2024-2025 | Hadlima, Renflexis |
| Pfizer INC. | $118.82 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $117.39 | 2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $115.30 | 2025 | Acthar |
| Genzyme Corporation | $106.96 | 2025 | |
| Insulet Corporation | $67.01 | 2021 | |
| Si-Bone, INC. | $66.11 | 2024 | |
| Invivyd INC | $51.18 | 2025 | Pemgarda |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $29.81 | 2022 | |
| Lilly USA, LLC | $26.96 | 2024 | Taltz |
| Boston Scientific Corporation | $24.75 | 2024 | |
| Tersera Therapeutics LLC | $22.26 | 2025 | Quzyttir |
| Radius Health, INC. | $19.41 | 2025 | Tymlos |
| Stryker Corporation | $19.01 | 2023 | Monterey Al |
| Tonix Medicines, INC. | $18.60 | 2025 | Tonmya |
| Medtronic, INC. | $16.78 | 2022 | |
| Aesculap, INC. | $16.47 | 2022 | |
| Genentech USA, INC. | $14.81 | 2025 | Gazyva |
| Janssen Pharmaceuticals, INC | $1.03 | 2025 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Benish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.